Cyclacel Pharmaceuticals Stock Price. Everything You Need To Know About The Cyclacel Pharmaceuticals Stock!
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company headquartered in Berkeley Heights, New Jersey. The company is dedicated to the development of cancer medicines using advanced techniques based on cell cycle, transcriptional regulation, and mitosis control biology.
Cyclacel Pharmaceuticals is currently focused on developing two programs to advance its mission. The first program, Transcriptional Regulation, is working on evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, for use in treating solid tumors and hematological malignancies. This innovative program is aimed at developing new treatment options for patients with limited therapeutic options.
The second program is the Mitosis Regulation program, which includes plogosertib, a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor. This program is designed to develop effective treatments for solid tumors and hematological malignancies. Plogosertib has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and impressive efficacy in human tumor xenografts at non-toxic doses. Additionally, the company’s translational biology program supports the development of plogosertib in acute leukemias and solid tumors.
It’s important to stay up to date on the latest developments in the biopharmaceutical industry, including stocks share price today, premarket trends, and market cap. While we cannot provide financial advice, it’s important to research stocks like Cyclacel Pharmaceuticals to make informed decisions about investments. By keeping up to date on the latest developments, investors can make informed decisions that align with their investment goals.
Cyclacel Pharmaceuticals Stock Price. Everything You Need To Know About The Cyclacel Pharmaceuticals Stock! performance
- Employees 0
- Company HQ Berkeley Heights
- Website http://www.cyclacel.com/
- CYCC Asset Type Common Stock
- CYCC Market Capitalization 2.8M
- Earnings Per Share -26.75
- Dividends Per Share None
- Dividend Date 2020-04-15
- Quarterly Earnings Growth 0
Looking to invest in Cyclacel Pharmaceuticals from Malaysia, Thailand, Indonesia, or Vietnam? Look no further! At Zorion, we provide retail investors with the resources and insights they need to make informed investment decisions. Cyclacel Pharmaceuticals is a promising stock worth considering. As a biopharmaceutical company, Cyclacel focuses on developing innovative therapies for the treatment of cancer and other serious diseases. Their extensive research and development capabilities make them a key player in the healthcare industry. With Zorion’s investment recommendations and educational materials, you can gain the knowledge necessary to invest wisely. Start your investment journey with us and explore the potential of Cyclacel Pharmaceuticals.
